vs
Side-by-side financial comparison of ON Semiconductor (ON) and Zoetis (ZTS). Click either name above to swap in a different company.
Zoetis is the larger business by last-quarter revenue ($2.4B vs $1.6B, roughly 1.5× ON Semiconductor). Zoetis runs the higher net margin — 25.3% vs 16.4%, a 8.8% gap on every dollar of revenue. On growth, Zoetis posted the faster year-over-year revenue change (3.0% vs -10.0%). Zoetis produced more free cash flow last quarter ($732.0M vs $372.4M). Over the past eight quarters, Zoetis's revenue compounded faster (4.4% CAGR vs -12.3%).
Fairchild Semiconductor International, Inc. was an American semiconductor company based in San Jose, California. It was founded in 1957 as a division of Fairchild Camera and Instrument by the "traitorous eight" who defected from Shockley Semiconductor Laboratory. It became a pioneer in the manufacturing of transistors and of integrated circuits. Schlumberger bought the firm in 1979 and sold it to National Semiconductor in 1987; Fairchild was spun off as an independent company again in 1997. I...
Zoetis Inc. (/zō-EH-tis/) is an American drug company, the world's largest producer of medicine and vaccinations for pets and livestock. The company was a subsidiary of Pfizer, the world's largest drug maker, but with Pfizer's spinoff of its 83% interest in the firm it is now a completely independent company. The company directly markets its products in approximately 45 countries, and sells them in more than 100 countries. Operations outside the United States accounted for 50% of the total re...
ON vs ZTS — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.6B | $2.4B |
| Net Profit | $255.0M | $603.0M |
| Gross Margin | 37.9% | 70.2% |
| Operating Margin | 17.0% | 31.9% |
| Net Margin | 16.4% | 25.3% |
| Revenue YoY | -10.0% | 3.0% |
| Net Profit YoY | -32.9% | 3.8% |
| EPS (diluted) | $0.63 | $1.37 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.6B | $2.4B | ||
| Q3 25 | $1.5B | $2.4B | ||
| Q2 25 | $1.4B | $2.5B | ||
| Q1 25 | — | $2.2B | ||
| Q4 24 | $1.7B | $2.3B | ||
| Q3 24 | $1.8B | $2.4B | ||
| Q2 24 | $1.7B | $2.4B | ||
| Q1 24 | $1.9B | $2.2B |
| Q4 25 | $255.0M | $603.0M | ||
| Q3 25 | $170.3M | $721.0M | ||
| Q2 25 | $-486.1M | $718.0M | ||
| Q1 25 | — | $631.0M | ||
| Q4 24 | $379.9M | $581.0M | ||
| Q3 24 | $401.7M | $682.0M | ||
| Q2 24 | $338.2M | $624.0M | ||
| Q1 24 | $453.0M | $599.0M |
| Q4 25 | 37.9% | 70.2% | ||
| Q3 25 | 37.6% | 71.5% | ||
| Q2 25 | 20.3% | 73.6% | ||
| Q1 25 | — | 72.0% | ||
| Q4 24 | 45.2% | 69.5% | ||
| Q3 24 | 45.4% | 70.6% | ||
| Q2 24 | 45.2% | 71.7% | ||
| Q1 24 | 45.8% | 70.6% |
| Q4 25 | 17.0% | 31.9% | ||
| Q3 25 | 13.2% | 37.0% | ||
| Q2 25 | -39.7% | 36.7% | ||
| Q1 25 | — | 36.5% | ||
| Q4 24 | 23.7% | 31.6% | ||
| Q3 24 | 25.3% | 36.6% | ||
| Q2 24 | 22.4% | 33.0% | ||
| Q1 24 | 28.2% | 34.1% |
| Q4 25 | 16.4% | 25.3% | ||
| Q3 25 | 11.6% | 30.0% | ||
| Q2 25 | -33.6% | 29.2% | ||
| Q1 25 | — | 28.4% | ||
| Q4 24 | 22.1% | 25.1% | ||
| Q3 24 | 22.8% | 28.6% | ||
| Q2 24 | 19.5% | 26.4% | ||
| Q1 24 | 24.3% | 27.4% |
| Q4 25 | $0.63 | $1.37 | ||
| Q3 25 | $0.41 | $1.63 | ||
| Q2 25 | $-1.15 | $1.61 | ||
| Q1 25 | — | $1.41 | ||
| Q4 24 | $0.88 | $1.29 | ||
| Q3 24 | $0.93 | $1.50 | ||
| Q2 24 | $0.78 | $1.37 | ||
| Q1 24 | $1.04 | $1.31 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $2.9B | — |
| Total DebtLower is stronger | $3.4B | — |
| Stockholders' EquityBook value | $7.9B | $3.3B |
| Total Assets | $13.0B | $15.5B |
| Debt / EquityLower = less leverage | 0.43× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $2.9B | — | ||
| Q3 25 | $2.8B | $2.1B | ||
| Q2 25 | $3.0B | $1.4B | ||
| Q1 25 | — | $1.7B | ||
| Q4 24 | $3.0B | $2.0B | ||
| Q3 24 | $2.8B | $1.7B | ||
| Q2 24 | $2.7B | $1.6B | ||
| Q1 24 | $2.6B | $2.0B |
| Q4 25 | $3.4B | — | ||
| Q3 25 | $3.4B | — | ||
| Q2 25 | $3.4B | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $3.4B | — | ||
| Q3 24 | $3.4B | — | ||
| Q2 24 | $3.4B | — | ||
| Q1 24 | $3.4B | — |
| Q4 25 | $7.9B | $3.3B | ||
| Q3 25 | $7.9B | $5.4B | ||
| Q2 25 | $8.0B | $5.0B | ||
| Q1 25 | — | $4.7B | ||
| Q4 24 | $8.8B | $4.8B | ||
| Q3 24 | $8.6B | $5.2B | ||
| Q2 24 | $8.3B | $5.0B | ||
| Q1 24 | $8.1B | $5.1B |
| Q4 25 | $13.0B | $15.5B | ||
| Q3 25 | $13.1B | $15.2B | ||
| Q2 25 | $13.3B | $14.5B | ||
| Q1 25 | — | $14.1B | ||
| Q4 24 | $14.1B | $14.2B | ||
| Q3 24 | $13.9B | $14.4B | ||
| Q2 24 | $13.7B | $14.2B | ||
| Q1 24 | $13.5B | $14.3B |
| Q4 25 | 0.43× | — | ||
| Q3 25 | 0.43× | — | ||
| Q2 25 | 0.42× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.38× | — | ||
| Q3 24 | 0.39× | — | ||
| Q2 24 | 0.41× | — | ||
| Q1 24 | 0.42× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $418.7M | $893.0M |
| Free Cash FlowOCF − Capex | $372.4M | $732.0M |
| FCF MarginFCF / Revenue | 24.0% | 30.7% |
| Capex IntensityCapex / Revenue | 3.0% | 6.7% |
| Cash ConversionOCF / Net Profit | 1.64× | 1.48× |
| TTM Free Cash FlowTrailing 4 quarters | $1.4B | $2.3B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $418.7M | $893.0M | ||
| Q3 25 | $184.3M | $938.0M | ||
| Q2 25 | $602.3M | $486.0M | ||
| Q1 25 | — | $587.0M | ||
| Q4 24 | $579.7M | $905.0M | ||
| Q3 24 | $465.8M | $951.0M | ||
| Q2 24 | $362.2M | $502.0M | ||
| Q1 24 | $498.7M | $595.0M |
| Q4 25 | $372.4M | $732.0M | ||
| Q3 25 | $106.1M | $805.0M | ||
| Q2 25 | $454.7M | $308.0M | ||
| Q1 25 | — | $438.0M | ||
| Q4 24 | $434.8M | $689.0M | ||
| Q3 24 | $293.6M | $784.0M | ||
| Q2 24 | $207.7M | $370.0M | ||
| Q1 24 | $276.3M | $455.0M |
| Q4 25 | 24.0% | 30.7% | ||
| Q3 25 | 7.2% | 33.5% | ||
| Q2 25 | 31.5% | 12.5% | ||
| Q1 25 | — | 19.7% | ||
| Q4 24 | 25.2% | 29.7% | ||
| Q3 24 | 16.7% | 32.8% | ||
| Q2 24 | 12.0% | 15.7% | ||
| Q1 24 | 14.8% | 20.8% |
| Q4 25 | 3.0% | 6.7% | ||
| Q3 25 | 5.3% | 5.5% | ||
| Q2 25 | 10.2% | 7.2% | ||
| Q1 25 | — | 6.7% | ||
| Q4 24 | 8.4% | 9.3% | ||
| Q3 24 | 9.8% | 7.0% | ||
| Q2 24 | 8.9% | 5.6% | ||
| Q1 24 | 11.9% | 6.4% |
| Q4 25 | 1.64× | 1.48× | ||
| Q3 25 | 1.08× | 1.30× | ||
| Q2 25 | — | 0.68× | ||
| Q1 25 | — | 0.93× | ||
| Q4 24 | 1.53× | 1.56× | ||
| Q3 24 | 1.16× | 1.39× | ||
| Q2 24 | 1.07× | 0.80× | ||
| Q1 24 | 1.10× | 0.99× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ON
| Industrial Segment | $426.3M | 27% |
| Other End Markets Segment | $337.3M | 22% |
| Intelligent Sensing Segments | $284.0M | 18% |
| Direct Customers | $282.4M | 18% |
| Intelligent Sensing Group | $230.0M | 15% |
ZTS
| Other | $1.3B | 56% |
| Livestock | $234.0M | 10% |
| Pain Sedation | $209.0M | 9% |
| Other Pharmaceuticals | $188.0M | 8% |
| Swine | $125.0M | 5% |
| Poultry | $117.0M | 5% |
| Fish | $81.0M | 3% |
| Other Non Pharmaceuticals | $70.0M | 3% |
| Manufactured Product Other | $18.0M | 1% |
| Medicated Feed Additives | $12.0M | 1% |
